Measure of adherence to direct-acting antivirals as a predictor of the effectiveness of hepatitis C treatment

被引:8
|
作者
Campos Fernandez de Sevilla, Maria Angeles [1 ]
Gallego Ubeda, Marta [1 ]
Tovar Pozo, Maria [1 ]
Garcia-Cabrera, Emilio [2 ]
Monje Garcia, Beatriz [1 ]
Tutau Gomez, Federico [3 ]
Delgado Tellez de Cepeda, Laura [3 ]
Iglesias-Peinado, Irene [4 ]
机构
[1] Hosp Univ Henares, Pharm Dept, Clin Pharm, Madrid, Spain
[2] Delos Clin, Seville, Spain
[3] Hosp Univ Henares, Pharm Dept, PharmD & Clin Pharm, Madrid, Spain
[4] Univ Complutense Madrid, Fac Pharm, PharmD, Madrid, Spain
关键词
Adherence; Antivirals; Chronic hepatitis C; Infectious diseases; Spain; HIV-INFECTED PATIENTS; COHORT; METAANALYSIS; INTERFERON; SOFOSBUVIR; RIBAVIRIN; VALIDITY; THERAPY;
D O I
10.1007/s11096-019-00917-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Adherence to direct-acting antivirals could be a predictor response to these treatments in hepatitis C. Objective To assess the ability of three methods of measuring adherence to direct-acting antivirals [pill counts, pharmacy dispensing record and Simplified Medication Adherence Questionnaire (SMAQ)] as predictors of their effectiveness. Setting Study conducted by the pharmacy department of the hospital. Methods: A retrospective study was performed. Patients >= 18 years with hepatitis C that started and completed treatment with direct-acting antivirals between the 1st-April-2015 and 28st-February-2016 were enrolled. To evaluate the predictive ability to obtain a response to treatment, Chi squared test, Mann-Whitney-U test and ROC-curves were used. Main outcome measure Adherence to antivirals was assessed by three methods and response to treatment, which was defined as obtaining a viral load of hepatitis C virus <= 15UI/ml at week 12 after the end of treatment. Results 128 patients were enrolled. The overall average adherence obtained with SMAQ (99.09%) was similar to the pill counts (96.40%, p = 0.043) and pharmacy dispensing record (91.10%, p = 0.02). There was no correlation between the percentage of patients considered as adherent by SMAQ (99.09%) and the achievement of response to treatment (96.40%, p = 0.999). The ROC-curve obtained for the pill count method shows a global area under the curve of 0.53. For pharmacy dispensing record method, patients with an adherence <= 66.66% have a high probability of not achieving response (sensitivity and specificity of 79.00% and 100.00%, respectively). Conclusions Pharmacy dispensing record is shown as the best indicator of adherence to predict therapeutic failure in our study.
引用
收藏
页码:1545 / 1554
页数:10
相关论文
共 50 条
  • [31] Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India
    Aggarwal, Rakesh
    Chen, Qiushi
    Goel, Amit
    Seguy, Nicole
    Pendse, Razia
    Ayer, Turgay
    Chhatwal, Jagpreet
    PLOS ONE, 2017, 12 (05):
  • [32] Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals
    Dobrowolska, Krystyna
    Brzdek, Michal
    Rzymski, Piotr
    Flisiak, Robert
    Pawlowska, Malgorzata
    Janczura, Jakub
    Brzdek, Kinga
    Zarebska-Michaluk, Dorota
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, : 833 - 852
  • [33] Treatment of hepatitis C in HIV patients in the new era of direct-acting antivirals
    Fernández-Montero J.V.
    Vispo E.
    Barreiro P.
    De Mendoza C.
    Labarga P.
    Soriano V.
    Current Hepatitis Reports, 2013, 12 (4) : 269 - 275
  • [34] Real-World Experiences with Direct-Acting Antivirals for Hepatitis C Treatment
    Daniel, Kimberly
    Rizvi, Syed
    Saeian, Kia
    HEPATOLOGY, 2017, 66 : 840A - 841A
  • [35] Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resources
    Marciano, S.
    Haddad, L.
    Borzi, S. M.
    D'Amico, C.
    Gaite, L. A.
    Aubone, M. V.
    Sirotinsky, M. E.
    Ratusnu, N.
    Frola, M. S.
    Aparicio, M. C.
    Rios, B.
    Anselmo, M. N.
    Hansen, R.
    De Filippi, S.
    Garcia Dans, C.
    de Labra, L.
    Peche, M. A.
    Strella, T. M.
    Ibanez Duran, M.
    Garcia Rosales, M. B.
    Dirchwolf, M.
    Galdame, O. A.
    Gadano, A. C.
    REVISTA DE GASTROENTEROLOGIA DE MEXICO, 2018, 83 (02): : 208 - 211
  • [36] EFFECTIVENESS AND SAFETY OF DIRECT-ACTING ANTIVIRALS IN PSYCHIATRIC HEPATITIS C VIRUS INFECTED PATIENTS
    Margusino-Framinan, Luis
    Bobadilla-Perez, Eva
    Carlos Yanez-Rubal, Juan
    Prieto-Perez, Andrea
    Cid-Silva, Purificacion
    Rodriguez-Sotelo, Alejandro
    Gimenez-Arufe, Victor
    Quiroga-Fernandez, Candela
    Isabel Sanclaudio-Luhia, Ana
    Novo-Ponte, Ana
    Mena-De-Cea, Alvaro
    Martin-Herranz, Isabel
    Castro-Iglesias, Angeles
    HEPATOLOGY, 2019, 70 : 966A - 966A
  • [37] Barriers to Treatment of Chronic Hepatitis C with Direct-Acting Antivirals in an Urban Clinic
    Malespin, Miguel H.
    Harris, Ciel
    Kanar, Ozdemir
    de Melo, Silvio W., Jr.
    Nelson, David R.
    Cotler, Scott
    HEPATOLOGY, 2017, 66 : 325A - 325A
  • [38] Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C
    Li, Chunhong
    Liang, Jing
    Xiang, Huiling
    Chen, Haiyan
    Tian, Jie
    MEDICINE, 2020, 99 (48) : E23384
  • [39] Prescribing trends in direct-acting antivirals for the treatment of hepatitis C in Ontario, Canada
    Tadrous, Mina
    Mason, Kate
    Dodd, Zoe
    Guyton, Mary
    Powis, Jeff
    McCormack, Daniel
    Gomes, Tara
    CANADIAN LIVER JOURNAL, 2021, 4 (01): : 51 - 58
  • [40] Direct-Acting Antivirals for Hepatitis C Treatment in Kidney Transplant Recipients.
    Goyal, N.
    Huepfel, W.
    Tierney, A.
    Issa, N.
    Lake, J.
    Thompson, J.
    Hassan, M.
    Ibrahim, H.
    Kukla, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 791 - 792